Statins and stroke prevention

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 10, 2009, Pages 1231-1243

  Paciaroni, Maurizio ^a   Bogousslavsky, Julien ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Swiss Medical Network   (Switzerland)

Author keywords

Prevention; Statin; Stroke; Vascular disease

Indexed keywords

ALTEPLASE; AMLODIPINE; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET THERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ELDERLY CARE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRIMARY PREVENTION; RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANTICHOLESTEREMIC AGENTS; CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STROKE;

EID: 70449727675     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.106     Document Type: Review

References (88)

1. Kannel WB. Contributions of the Framingham Study of the conquest of coronary artery disease. Am. J. Cardiol. 62, 1109-1112 (1988).
2. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factors categories. Circulation 97, 1837-1847 (1998).
3. Enbergs A, Burger R, Reinecke H, Borggrefe M, Breithardt G, Kerber S. Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic ana lysis of subjects aged 40-70 years referred for catheter ablation therapy. Eur. Heart J. 21, 45-52 (2000). (Pubitemid 30042668)
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
5. Sacks FM, Pfeffer MA, Moyè LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 336, 1001-1009 (1996).
6. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349-1357 (1998).
7. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301-1307 (1995).
8. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623-1630 (2002). (Pubitemid 35379733)
9. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279, 1615-1622 (1998). (Pubitemid 28248586)
10. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
11. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorva statin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOTLLA): a multicenter randomized controlled trial. Lancet 364, 1149-1158 (2003).
12. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-ana lysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366, 1267-1278 (2005). •• Review and update of meta-analysis of statins for stroke prevention.
13. Karam JG, Loney-Hutchinson L, McFarlane SI; Stroke Prevetion by Aggressive Reduction in Cholestrol Levels (SPARCL) Investigators. High-dose atorva statin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559 (2006). •• First study that evaluated the use of statins in secondary prevention of stroke.
14. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 36, 1298-1300 (2005). • Emphasized the pleiotropic effect of statins.
15. Amarenco P, Lavallée P, Touboul PJ. Stroke prevention, blood cholesterol and statins. Lancet Neurol. 3, 271-278 (2004). •• Review and update of meta-analysis of statins for stroke prevention.
16. Bellosta S, Ferri N, Bernini F et al. Non-lipid-related effects of statins. Ann. Med. 32, 164-176 (2000).
17. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke. Lancet 346, 647-1653 (1995).
18. Sacco RL, Benson RT, Kargman DE et al. High density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 285, 2729-2735 (2001).
19. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 309, 11-15 (1994). (Pubitemid 2094096)
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischemic heart disease and stroke: systematic review and meta-ana lysis. BMJ 326, 1423-1429 (2003).
21. Wolf PA. Epidemiology of stroke. In: Stroke: Pathophysiology, Diagnosis and Management (4th Edition). Mohr JP, Choi DW, Grotta JC et al. (Eds). Churchill Livingstone, NY, USA (2004).
22. Iso H, Jacobs DR, Wentworth D et al. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the Muliple Risk Factor Intervention Trial. N. Engl. J. Med. 320, 904-910 (1989). (Pubitemid 19101595)
23. Amarenco P, Tonkin AM. Statins for stroke prevention. Disappointment and hope. Circulation 109 (Suppl. III), III44-III49 (2004).
24. Zureik M, Touboul PJ, Bonithon-Kopp C et al. Cross-sectional and 4 year longitudinal associations between brachial pulse pressure and common carotid intima-media thickness in a general population. The EVA study. Stroke 30, 550-555 (1999). (Pubitemid 29115391)
25. Amarenco P, Labreuche J, Lavallée P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis. Systematic review and up-to-date meta-ana lysis. Stroke 35, 2902-2909 (2004). (Pubitemid 39565192)
26. Kang S, Wu Y, Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-ana lysis. Atherosclerosis 177, 433-442 (2004). (Pubitemid 39505278)
27. Sillesen H, Amarenco P, Hennerici MG et al. Atorva statin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. Stroke 39, 3297-3302 (2008).
28. Tan TY, Kuo YL, Lin WC, Chen TY. Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis. J. Neurol. 256, 187-193 (2009).
29. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103, 926-933 (2001). (Pubitemid 32183796)
30. Lima JAC, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging - monitored therapy. Circulation 110, 2336-2341 (2004). (Pubitemid 39407336)
31. Pitt B, Mancini GB, Ellis SG et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26, 1133-1139 (1995).
32. Kimura M, Kurose I, Russell J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 17, 1521-1526 (1997). (Pubitemid 27387772)
33. Lehr HA, Seemuller J, Hubner C, Menger MD, Messmer K. Oxidized LDL-induced leukocyte/endothelium interaction in vivo involves the receptor for platelet activating factor. Arterioscler. Thromb. 13, 1013-1018 (1993). (Pubitemid 23195803)
34. Notarbartolo A, Davi G, Averna M et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15, 247-251 (1995).
35. Mayer J, Eller T, Brauer P et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann. Hematol. 64, 196-201 (1992).
36. Vaughan CJ. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am. J. Cardiol. 91(Suppl.), B23-B29 (2003).
37. Sterzer P, Meintzschel F, Rosler A et al. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 32, 2817-2820 (2001). (Pubitemid 33134471)
38. Lavallée PC, Labreuche J, Gorgora-Rivera F et al. Placebo-controlled trial of high-dose atorva statin in patients with severe cerebral small vessel disease. Stroke 40, 1721-1728 (2009).
39. Herbert PR, Gazianon JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch. Intern. Med. 155, 50-55 (1995).
40. Cheung BMY, Lauder IJ, Lau CP, Kumana CR. Meta-ana lysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacol. 57, 640-651 (2004).
41. White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Engl. J. Med. 343, 317-326 (2000).
42. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007 (2002).
43. Gotto AM Jr. Ongoing clinical trials of statins. Am. J. Cardiol. 88(Suppl.), F36-F40 (2001).
44. Amarenco P, Bogousslavsky J, Callahan AS et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL). Cerebrovasc. Dis. 16, 389-395 (2003).
45. Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) Study. Circulation 99, 216-223 (1999).
46. The Kyushu Lipid Intervention Study Group. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study. J. Atheroscler. Thromb. 7, 110-121 (2000).
47. Schwartz GG, Olsson AG, Ezekowitz MD et al.; the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorva statin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711-1718 (2001).
48. Waters D, Schwart GG, Olsson AG et al. for the MIRACL Study Investigators. Effects of atorva statin on stroke in patients with unstable angina on non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106, 1690-1695 (2002).
49. GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto del Miocardio) Study Investigators. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital. Heart J. 1, 810-820 (2000).
50. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A to Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am. Heart J. 142, 211-217 (2001). (Pubitemid 32706275)
51. De Lemos JA, Blazing MA, Wiviott SD et al.; A to Z Investigators. Early intensive versus a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292, 1307-1316 (2004).
52. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorva statin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: the greek Atorva statin and Coronary Heart Disease Evaluation (GREACE) Study. Curr. Med. Res. Opin. 18, 220-228 (2002).
53. Byington RP, Davis BR, Plehn JF et al.; the PPP Investigators. Reduction of stroke events with pravastatin. Circulation 103, 387-392 (2001).
54. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorva statin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
55. Pasternak RC. The ALLHAT Lipid Lowering Trial. Less is less. JAMA 288, 3042-3044 (2002).
56. Saver PS, Dahlof B, Poulter NR et al.; the ASCOT Investigators: prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 361, 1149-1158 (2003).
57. Colhoun HM, Beteridge DJ, Durrington PN et al.; CARDS Investigators. Primary prevention of cardiovascular disease with atorva statin in Type 2 diabetes in the Collaborative Atorva statin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
58. Koren MJ, Hunninghake DB; the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The ALLIANCE Study. J. Am. Coll. Cardiol. 44, 1772-1779 (2004).
59. Cannon CP, Braunwald E, McCabe CH et al.; the Pravastatin or Atorva statin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction (TIMI) 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
60. LaRosa J, Grundy SM, Waters DD et al.; the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorva statin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
61. Pedersen TR, Faergeman O, Kastelein JJ et al.; the Incremental Decrease in End Point Through Aggressive Lipid Lowering (IDEAL) Study Group (2005). High-dose atorva statin versus usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 294, 2437-2445 (2005).
62. Nakamura H, Arakawa K, Itakura A et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368, 1155-1163 (2006). (Pubitemid 44444932)
63. Knopp RH, D'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular and points in subjects with Type 2 diabetes. Diabetes Care 29, 1478-1485 (2006).
64. Bowman L, Armitage J, Bulbulia R et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH): characteristics of a randomized trial among 12,064 myocardial infarction survivors. Am. Heart J. 154, 815-823 (2007).
65. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
66. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk. JAMA 295, 74-80 (2006).
67. Bays H. Statin safety: an overview and assessment of the data - 2005. Am. J. Cardiol. 97(Suppl.), C6-C26 (2006).
68. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 289, 1681-1690 (2003).
69. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-ana lysis of randomized controlled trials. Am. J. Med. 117, 596-606 (2004). (Pubitemid 39304211)
70. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins and cholesterol: a meta-ana lysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28, 946-950 (1997).
71. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch. Intern. Med. 157, 1305-1310 (1997).
72. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and update meta-ana lysis of statins for stroke prevention. Lancet Neurol. 8,453-463 (2009). •• Review and update of meta-analysis of statins for stroke prevention.
73. Heart Protection Study Collaborative Group. Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363, 757-767 (2004).
74. Coull BM. Statin therapy after acute ischemic stroke in the Heart Protection Study. Stroke 35, 2233-2234 (2004).
75. Paciaroni M. Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc. Dis. 24, 170-182 (2007). •• Review and update of meta-analysis of statins for stroke prevention.
76. Kent DM. Editorial. An equal opportunity for the initiation of statin therapy. N. Engl. J. Med. 355, 613-615 (2006).
77. Giroud M, Creisson E, Fayolle H et al. Risk factors for primary cerebral hemorrhage: a population-based study - the Stroke Registry of Dijon. Neuroepidemiology 14, 20-26 (1995).
78. Thrift AG, McNeil JJ, Forbes A, Donnan GA; Melbourne Risk Factor Study (MERFS) Group. Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Stroke 27, 2020-2025 (1996).
79. Vergouwen MDI, De Haan RJ, Vermeulen M et al. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39, 497-502 (2008). (Pubitemid 351619482)
80. Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 70, 2364-2370 (2008).
81. Bang OY, Saver JL, Liebeskind DS et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 68, 737-742 (2007).
82. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst. Rev. (3), CD002091 (2009).
83. Adams RJ, Albers G, Alberts MJ et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39, 1647-1652 (2008).
84. Elkind MS, Sacco RL, Macarthur RB et al. High-dose lovastatin for acute ischemic stroke: results of the Phase I Dose Escalation Neuroprotection with Statin Therapy for acute recovery trial (NeuSTART). Cerebrovasc. Dis. 28, 266-275 (2009).
85. Ovbiagele B, Javer JL. Intensive statin therapy after stroke or transient ischemic attack. A SPARCLing success! Stroke 38, 1110-1112 (2007). (Pubitemid 46568486)
86. Ballantyne CM, Abate N, Yuan Z et al. Dose comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorva statin in patients with hypercholesterolemia: the Vytorin Versus Atorva statin (VYVA) study. Am. Heart J. 149, 464-473 (2005). (Pubitemid 40585409)
87. Freiberg JJ, Tybjærg-Hansen A, Jensen JS et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300, 2142-2152 (2008).
88. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341, 410-418 (1999). (Pubitemid 29362514)